临床试验/NCT07828314

NCT07828314已完成不适用

Patient Priorities in the Management of Early Oesophageal Cancer: A Discrete Choice Study

Portsmouth Hospitals NHS Trust1 个研究点分布在 1 个国家目标入组 118 人开始时间: 2025年8月6日最近更新: 2026年9月18日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Portsmouth Hospitals NHS Trust
入组人数: 118
试验地点: 1
主要终点: Patient priorities

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Understanding patient priorities is important to providing thorough, individualised care in oesophageal cancer. We aim to use questionnaires to explore what is important to patients when considering radical surgery for oesophageal cancer, and to analyse how patients interpret the risk explained to them during the consent process

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Under care of local MDT for monitoring/surveillance/treatment of Barretts/dysplasia/oesophageal cancer
•able to communicate in English Language

排除标准

•Unable or unwilling to give informed consent

研究组 & 干预措施

Stage 1

Semi-structured interviews

干预措施: Semi-structured interview (Behavioral)

Stage 2

Discrete choice experiment

干预措施: Discrete Choice Experiment (Behavioral)

结局指标

主要结局

Patient priorities

时间窗: 6 months

Interview responses and responses from discrete choice experiment.

次要结局

未报告次要终点

研究者

发起方

Portsmouth Hospitals NHS Trust

申办方类型

Other Gov

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

尚未招募

不适用

Payment from personal funds for Esophageal cancer treatment: A multicentric study in Northeast India

CTRI/2025/10/095809National Cancer Grid400

尚未招募

2 期

Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerEsophageal Squamous Cell Carcinoma

NCT07653451Peking University Cancer Hospital & Institute90

尚未招募

不适用

An observational study on effect of high dose PPI on severe eGERD

CTRI/2025/03/081769Dr Reddys Laboratories Limited500

招募中

不适用

Treatment Outcomes for Portal Hypertension Esophageal and Gastric Varices

NCT07358663Shanghai Zhongshan Hospital1,384

尚未招募

2 期

A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based ChemotherapyEsophageal Squamous Carcinoma Cell

NCT07688291Beijing GoBroad Hospital40